drugset / Trial / NCT07099534

Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder

NCT07099534

Phase 2 Not yet recruiting 38 enrolled University Hospital, Toulouse
NaSingle-groupOpen-labelTreatment

Summary

The main objective of this pilot study is to evaluate at D9 the evolution of BPD symptoms' intensity(scale BSL-23) in severe BPD patients, after two Ketamine infusions (0.5mg/kg at H0 and H24). The intervention is combined with the first level standard of care : Good Psychiatric Management (GPM). Patients are followed up to 3 months by regular visits conducted by a psychiatrist. Secondary outcomes are monitored including BPD symptoms at different times, suicidal ideation, depressiv symptoms, healthcare use and adverse effects.

Timeline

Start
2026-09-01
Primary completion
2028-09-30
Completion
2028-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous